AMFX-200 for Acute Spinal Cord Injury
Our lead candidate is a neuroregenerative treatment for acute spinal cord injury (SCI) and other neurological conditions
~18K people in the US, and ~500K globally, experience SCI each year leading to long-term paralysis
Disproportionately impacts younger people, with an average age at injury of only ~44 years old​
​There is no FDA-approved therapeutic available to restore function after SCI ​​​
AMFX-200 takes an entirely new approach to neural regeneration by combining pharmacological action of peptide drugs and a nanofiber scaffold into one therapy
Demonstrates unprecedented motor function recovery in preclinical models of SCI​​​
​Reduces neuropathic pain and inflammatory responses in the spinal cord​​​
​Prevents formation of glial scar tissue which inhibits neural function​​
Representative recovery of motor function in preclinical model of acute SCI:
Control mice (left) have no hind limb function after injury. Mice treated with AMFX-200 (right) recover significant motor function, including plantar stepping and weight bearing in their hind limbs. ​​​
Video credit: Northwestern University.
Learn more:
AMFX-100 for Spinal Fusion Surgery
Our off-the-shelf bone graft substitute enables orthopedic surgeons to perform spinal fusion procedures without using donor tissue or recombinant proteins
~0.5 million spinal fusion procedures are performed each year in the US
​Fusion procedures are used to treat back pain caused by degenerative disc disease​
Current approaches such as recombinant proteins have safety issues that limit their use
AMFX-100 has received a Breakthrough Device Designation from the FDA
Representative bone growth in preclinical sheep model of interbody spinal fusion:
Micro-CT
Histology
When implanted between vertebrae after removal of a diseased disc, AMFX-100 generates new bone tissue to fuse vertebrae together, as seen in CT and histology images.